• # LGM Pharma is a Dactinomycin CAS# 50-76-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Dactinomycin
  • CAS #: 50-76-0
  • Mode of Action:

    Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.

  • Pharmacodynamics:

    Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.

  • Metabolism:

    hepatic

  • Toxicity:

    hepatoxicity

  • IUPAC: 1-N, 9-N-bis[(6S, 9R, 10S, 13R, 18aS)-2, 5, 9-trimethyl-1, 4, 7, 11, 14-pentaoxo-6, 13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2, 1-i]1-oxa-4, 7, 10, 13-tetraazacyclohexadecan-10-yl]-2-amino-4, 6-dimethyl-3-oxo-3H-phenoxazine-1, 9-dicarboxamide
  • ATC: L01DA01
  • PubChem: 2019
  • DrugBank: DB00970 (APRD00124)
  • Formula: C22H29FO4
  • Molecular Mass: 1255.417
  • Synonyms: ActD Actinomycin C1 Actinomycin D Dactinomicina [INN-Spanish] Dactinomycine [INN-French] Dactinomycinum [INN-Latin]
  • SMILES: [H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
  • AHFS Code: 10:00.0
  • InChl: RJURFGZVJUQBHK-IIXSONLDSA-N
  • General Reference:

    1. Sobell HM: Actinomycin and DNA transcription. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5328-31. Pubmed
    2. Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose MF: Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8. Pubmed
    3. Abd El-Aal HH, Habib EE, Mishrif MM: Wilmsê tumor: the experience of the pediatric unit of Kasr El-Aini center of radiation oncology and nuclear medicine (NEMROCK). J Egypt Natl Canc Inst. 2005 Dec;17(4):308-14. Pubmed
    4. Khatua S, Nair CN, Ghosh K: Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J Pediatr Hematol Oncol. 2004 Nov;26(11):777-9. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements